Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AD-221 and AD-221A in Primary Hypercholesterolemia
NCT05131997Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin, ezetimibe in hypercholesterolemia, sponsored by Addpharma, Inc.. Started Nov 2021; status: completed.
02
Drugs
atorvastatinezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05131997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131997.